News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Sarah Sammons: RLY2608 and Fulvestrant in HR+/HER2- PIK3CA mutant breast cancer
Sarah Sammons/medicine.duke.edu
Jun 3, 2025, 13:23

Sarah Sammons: RLY2608 and Fulvestrant in HR+/HER2- PIK3CA mutant breast cancer

Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared on X:

“Major unmet need for Mutant Specific PIK3CA inhibitors with improved efficacy and side effects for our patients.
RLY2608 and Fulvestrant in post-CDK4/6 HR+, HER2- PIK3CA mutant breast cancer.
ORR close to 40% post-CDK4/6.
Median PFS 10 months all comers, 11 months 2L, 18 months kinase mutant.
Side effects mostly low grade: hyperglycemia, nausea, fatigue. Little rash, oral mucositis, diarrhea.
Phase III opening at sites next week!”

Sarah Sammons: RLY2608 and Fulvestrant in HR+/HER2- PIK3CA mutant breast cancer

You can find more posts featuring Sarah Sammons on OncoDaily.

ASCO 2025 Breast Cancer cancer Fulvestrant OncoDaily Oncology PIK3CA inhibitors RLY2608 Sarah Sammons
Special Coverage
Oncolibrary
Jul 1, 2025, 12:44
MASCC 2025 Highlights: StrataXRT Prevents Severe Radiation Dermatitis in Large-Breasted Women Undergoing Prone Breast Radiotherapy
Blog
Jul 1, 2025, 10:46
INTERACT-EUROPE 100 Has Launched a New Round of Recruitment - European Cancer Organisation
Societies
Jul 1, 2025, 10:32
25 Posts Not To Miss From MASCC 2025
Blog
Jul 1, 2025, 10:30
Alina Comanescu: Urgent Call to Action - Don't Let Cancer Slip Off the EU Agenda
Blog
Jul 1, 2025, 10:16
Survivor Cindy Pursues Nursing in Ghana Fifteen Years After Kidney Cancer Diagnosis - World Child Cancer
Blog
Jul 1, 2025, 10:07
Treatment Optimisation: Making Cancer Treatment Accessible and Sustainable in Europe - EORTC
Blog
Jul 1, 2025, 09:57
Gevorg Tamamyan: To Me, MD Anderson Has Always Meant Dr. Kantarjian
Career
Jul 1, 2025, 09:56
Sidney Chahonyo is Breaking Barriers as the First Survivor on the Board of Childhood Cancer International
Blog
Jul 1, 2025, 09:34
Jasmine Kamboj: Congratulating the New Co-Leads of the Community of Practice Policy
Dialogues
Jul 1, 2025, 09:27
Top Biotechs at ASCO: Ruthie Davi on AI and Data Insights in Platinum-Resistant Ovarian Cancer
Blog
Jul 1, 2025, 09:25
Alexandre Chan's Final Reflection on MASCC 2025
Dialogues
Jul 1, 2025, 09:21
Women Leaders in Oncology: Nina Mojas on GSK’s Oncology Growth and Innovation Strategy